Galapagos expands drug discovery alliance with AstraZeneca

This is the second program between the two companies under an agreement signed in August 2006. In this new collaboration, BioFocus DPI will perform medicinal chemistry, computational chemistry and supporting biology and ADMET services for an AstraZeneca drug discovery program. The total contract value for Galapagos is E620,000.

BioFocus DPI provides adenoviral reagents for identification and validation of drug targets, compound libraries for drug screening as well as chemogenomics and ADMET database products in order to select targets and compounds for research.

“We have been pleased with the level of progress thus far and expect that BioFocus DPI’s expanded ADMET and predictive drug discovery capabilities will be key contributors in advancing this hit-to-lead program,” added Dr Lars-Erik Arvidsson, vice president of R&D Lund for AstraZeneca.